Table 1 Baseline Characteristics.
Bioprosthetic MVR group n = 21 | Mechanical MVR group n = 85 | p value | |
|---|---|---|---|
Age, years | 62.8 ± 9.3 | 57.6 ± 9.5 | 0.026 |
Female, n (%) | 10 (47.6) | 63 (74.1) | 0.019 |
BMI, kg/m2 | 25.3 ± 4.1 | 24.0 ± 3.3 | 0.120 |
SBP, mmHg | 131 ± 31 | 123 ± 21 | 0.187 |
DBP, mmHg | 76 ± 11 | 76 ± 11 | 0.913 |
CHA2DS2-VASc score, n (%) | 0.413 | ||
0 | 1 (4.8) | 9 (10.6) | |
≥ 1 score | 20 (95.2) | 76 (89.4) | |
HAS-BLED score | 1.0 (1.0–2.0) | 1.0 (0–1.0) | 0.002 |
AF type | 0.118 | ||
Paroxysmal, n (%) | 5 (23.8) | 36 (42.4) | |
Persistent, n (%) | 16 (76.2) | 49 (57.6) | |
Concomitant disease | |||
Rheumatic heart disease, n (%) | 9 (42.9) | 62 (72.9) | 0.007 |
Heart failure, n (%) | 7 (33.3) | 20 (23.5) | 0.356 |
Hypertension, n (%) | 13 (61.9) | 29 (34.1) | 0.020 |
Diabetes Mellitus, n (%) | 5 (23.8) | 11 (12.9) | 0.213 |
Ischemic stroke, n (%) | 1 (4.8) | 15 (17.6) | 0.140 |
CHD, n (%) | 7 (33.3) | 5 (5.9) | < 0.001 |
Echocardiography | |||
LAD, mm | 46.3 ± 6.4 | 46.5 ± 6.8 | 0.893 |
LVEDD, mm | 47.2 (44.1–50.3) | 45.4 (44.6–46.5) | 0.268 |
LVESD, mm | 32.2 (29.2–35.3) | 30.6 (29.5–31.7) | 0.309 |
LVEF, % | 55.8 ± 9.5 | 60.3 ± 7.4 | 0.021 |
Mitral orifice area, mm2 | 2.2 ± 0.4 | 2.7 ± 0.6 | < 0.001 |
Concomitant medication | |||
AADs, n (%) | 11 (52.4) | 67 (78.8) | 0.014 |
Rate-controlling drugs, n (%) | 11 (52.4) | 20 (23.5) | 0.009 |
ACEIs/ARBs, n (%) | 8 (38.1) | 20 (23.5) | 0.175 |
